MeSH D043183 - irritable bowel syndrome
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Salix Pharmaceuticals | Rifaximin | Xifaxan | 2024-06-19 | 2004-05-25 |  |  |
| Teva | Lubiprostone | Lubiprostone |  | 2022-01-18 |  |  |
| Mylan | Linaclotide | Linaclotide |  | 2021-02-09 |  |  |
| AbbVie | Linaclotide | Constella |  | 2012-11-26 |  |  |
| Linaclotide | Linzess | 2024-01-28 | 2012-08-30 | $1,004 M | Q4/23-Q3/24 | |
| Eluxadoline | Viberzi | 2025-03-14 | 2015-05-27 |  |  | |
| Allergan | Eluxadoline | Truberzi |  | 2016-09-19 |  |  |
| Aurobindo Pharma | Linaclotide | Linaclotide |  | 2023-02-07 |  |  |
| Dr Reddys Laboratories | Lubiprostone | Lubiprostone |  | 2022-02-08 |  |  |
1
2
3
4
5
>
Clinical Trials
Historical Success Rate
Phase 1
65%13/20
Phase 2
51%23/45
Phase 3
64%27/42
Approved: 13Overall Success rate: 21%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use